Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study Meeting Abstract
| Authors: | Passamonti, F.; Patriarca, A.; Knapper, S.; Rivera, C.; Scandura, J.; Devos, T.; Granacher, N.; Mead, A. J.; Oh, S.; Palmer, J. M.; Rampal, R.; Teichmann, L.; Cui, J.; Klein, S.; Colak, G.; Harrison, C. |
| Abstract Title: | Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.7019 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting abstract: 7019 -- Meeting also presented virtually -- Source: Cinahl |
